Profound Medical Corp. (PROF) News
Filter PROF News Items
PROF News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PROF News Highlights
- PROF's 30 day story count now stands at 2.
- Over the past 1 day, the trend for PROF's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about PROF are BASE and DEC.
Latest PROF News From Around the Web
Below are the latest news stories about PROFOUND MEDICAL CORP that investors may wish to consider to help them evaluate PROF as an investment opportunity.
Profound Medical Announces Pricing of US$20 Million Public Offering of Common SharesTORONTO, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”) today announced the pricing of its previously announced underwritten public offering (the “Offering”) of 2,666,667 common shares (the “Common Shares”) at a price to the public of US$7.50 per Common Share, led by healthcare focused institutional investors. Gross proceeds to the Company from the Offering are expected to be approximately US$20,000,000, prior to deducting underwriti |
Profound Medical Announces Proposed Public Offering of Common SharesTORONTO, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”) is pleased to announce the commencement of an underwritten public offering in the United States of common shares (the “Common Shares”) in the capital of the Company (the “Offering”). The Company intends to file a preliminary prospectus supplement (the “Preliminary Supplement”) to its short form base shelf prospectus dated March 23, 2022 (the “Base Shelf Prospectus”) in the Unite |
Profound Medical to Participate in the Stifel 2023 Healthcare ConferenceTORONTO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the Stifel 2023 Healthcare Conference on Wednesday, November 15, 2023 at 8:35 a.m. Eastern Time in NYC. The presentation will be broadcast live and archi |
Profound Medical Announces CMS Extension of Temporary ‘Code’ for TULSA to ASC SettingTORONTO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that, pursuant to the 2024 Final Rule published yesterday by the U.S. Centers for Medicare and Medicaid Services (“CMS”), use of HCPCS C code, C9734, previously established for the Hospital Outpatient Prospective Payment |
Profound Medical Announces Third Quarter 2023 Financial ResultsTORONTO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the third quarter ended September 30, 2023. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Rep |
Profound Medical to Release Third Quarter 2023 Financial Results on November 2 – Conference Call to FollowTORONTO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2023 financial results after market close on Thursday, November 2, 2023. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in |
Profound Medical 2023 Virtual Analyst & Investor Day AgendaTORONTO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today additional details regarding its Analyst & Investor Day event scheduled for Friday, October 13, 2023. The agenda will commence at 1:00 p.m. and is scheduled to conclude at approximately 3:30 p.m. Eastern Time. The program |
Investing in Profound Medical (TSE:PRN) a year ago would have delivered you a 134% gainIt hasn't been the best quarter for Profound Medical Corp. ( TSE:PRN ) shareholders, since the share price has fallen... |
Profound Medical Receives U.S. FDA 510(k) Clearance for TULSA-PRO® Thermal BoostThe first of the TULSA AI modules, Thermal Boost enables predictable, customized ablation at the prostate capsuleTORONTO, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA) for the Company’s T |
Save the Date: Profound Medical to Host Virtual Analyst & Investor Day on October 13TORONTO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will host an Analyst & Investor Day event on Friday, October 13, 2023 from 1:00 p.m. to approximately 3:30 p.m. Eastern Time. “The program will feature presentations on TULSA-PRO® and its unrivalled flexibility to treat a wide variety o |